425508009: Sitagliptin phosphate (substance)

SNOMED CT Concept\Substance\...

\Substance categorized by disposition\Substance with effector mechanism of action (substance)\Enzyme inhibitor\Hydrolase inhibitor\Peptide hydrolase inhibitor\...

\Proteinase inhibitor\Serine proteinase inhibitor\Sitagliptin phosphate (substance)

\Dipeptidyl peptidase IV inhibitor\Sitagliptin phosphate (substance)

\Substance categorised by structure\Chemical\Chemical categorized by structure (substance)\...

\Nitrogen and/or nitrogen compound (substance)\Nitrogen compound\Organic nitrogen compound\Azole (substance)\Substance with triazole structure (substance)\Sitagliptin phosphate (substance)

\Organic compound\Organic cyclic compound\Heterocyclic compound\Azole (substance)\Substance with triazole structure (substance)\Sitagliptin phosphate (substance)
\Organic compound\Organic nitrogen compound\Azole (substance)\Substance with triazole structure (substance)\Sitagliptin phosphate (substance)

Status: current, Not sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2007. Module: SNOMED CT core

Descriptions:

Id Description Lang Type Status Case? Module

2661573010 Sitagliptin phosphate (substance) en Fully specified name Active Entire term case insensitive (core metadata concept) SNOMED CT core

2675154010 Sitagliptin phosphate en Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) SNOMED CT core

3234201000005117 sitagliptinphosphat da Synonym (core metadata concept) Active Entire term case insensitive (core metadata concept) Danish module (core metadata concept)

Expanded Value Set

Outbound Relationships	Type	Target	Active	Characteristic	Refinability	Group	Values
Sitagliptin phosphate (substance)	Is a	Sitagliptin (substance)	false	Inferred relationship	Some
Sitagliptin phosphate (substance)	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Dipeptidyl peptidase IV inhibitor (disposition)	true	Inferred relationship	Some
Sitagliptin phosphate (substance)	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	Sitagliptin (substance)	true	Inferred relationship	Some
Sitagliptin phosphate (substance)	Is a	Dipeptidyl peptidase IV inhibitor	true	Inferred relationship	Some
Sitagliptin phosphate (substance)	Is a	Triazole derivative	false	Inferred relationship	Some
Sitagliptin phosphate (substance)	Is a	Serine proteinase inhibitor	true	Inferred relationship	Some
Sitagliptin phosphate (substance)	This attribute specifies the behavior that a substance will exhibit or participate in, given the appropriate context.	Serine proteinase inhibitor (disposition)	true	Inferred relationship	Some
Sitagliptin phosphate (substance)	Is a	Substance with triazole structure (substance)	true	Inferred relationship	Some

Inbound Relationships	Type	Active	Source	Characteristic	Refinability	Group
tablet sitagliptin 50 mg + metformin 1000 mg	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some
sitagliptin 50 mg + metformin 500 mg tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some
Product containing metformin and sitagliptin (medicinal product)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some
Sitagliptin (as sitagliptin phosphate) 100 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some
Sitagliptin (as sitagliptin phosphate) 25 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some
Product containing precisely sitagliptin (as sitagliptin phosphate) 50 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some
Sitagliptin (as sitagliptin phosphate) 25 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	1
Sitagliptin (as sitagliptin phosphate) 100 mg oral tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	1
Product containing precisely sitagliptin (as sitagliptin phosphate) 50 milligram/1 each conventional release oral tablet (clinical drug)	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	1
tablet sitagliptin 50 mg + metformin 1000 mg	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	2
tablet sitagliptin 50 mg + metformin 1000 mg	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	2
sitagliptin 50 mg + metformin 500 mg tablet	The clinically relevant part or whole of the substance that is intended to have a therapeutic action on or within the body. It excludes esters, salts or other non-covalent derivatives (such as a complex, chelate etc.), but may include secondary modifications.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	2
sitagliptin 50 mg + metformin 500 mg tablet	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	2
tablet sitagliptin 50 mg + metformin 1000 mg	This attribute represents an ingredient that is the part of the active ingredient that the strength of a given product is based upon.	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	1
Product containing precisely sitagliptin (as sitagliptin phosphate) 50 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Sitagliptin phosphate (substance)	Inferred relationship	Some	1
tablet sitagliptin 50 mg + metformin 1000 mg	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	1
Sitagliptin (as sitagliptin phosphate) 25 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Sitagliptin phosphate (substance)	Inferred relationship	Some	1
sitagliptin 50 mg + metformin 500 mg tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	2
Sitagliptin (as sitagliptin phosphate) 100 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Sitagliptin phosphate (substance)	Inferred relationship	Some	1
Sitagliptin phosphate monohydrate (substance)	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	True	Sitagliptin phosphate (substance)	Inferred relationship	Some
tablet sitagliptin 50 mg + metformin 1000 mg	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	False	Sitagliptin phosphate (substance)	Inferred relationship	Some	2
Metformin hydrochloride 500 mg and sitagliptin (as sitagliptin phosphate) 50 mg oral tablet	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Sitagliptin phosphate (substance)	Inferred relationship	Some	2
Product containing precisely metformin hydrochloride 850 milligram and sitagliptin (as sitagliptin phosphate) 50 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Sitagliptin phosphate (substance)	Inferred relationship	Some	2
Product containing precisely metformin hydrochloride 1 gram and sitagliptin (as sitagliptin phosphate) 50 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Sitagliptin phosphate (substance)	Inferred relationship	Some	2
Sitagliptin phosphate anhydrous (substance)	This attribute indicates that the concept is a structural modification of another concept, and that the substance's intrinsic physicochemical properties remain unchanged.	True	Sitagliptin phosphate (substance)	Inferred relationship	Some
Product containing precisely ertugliflozin (as ertugliflozin pidolate) 5 milligram and sitagliptin (as sitagliptin phosphate) 100 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Sitagliptin phosphate (substance)	Inferred relationship	Some	1
Product containing precisely ertugliflozin (as ertugliflozin pidolate) 15 milligram and sitagliptin (as sitagliptin phosphate) 100 milligram/1 each conventional release oral tablet (clinical drug)	The most specific description of a substance present in the manufactured dose form, before any dilution or transformation. It includes modifiers, such as salts, esters, polymers (e.g. pegylation), and/or solvates (including waters of hydration).	True	Sitagliptin phosphate (substance)	Inferred relationship	Some	1

This concept is not in any reference sets

Back to Start

Id	Description	Lang	Type	Status	Case?	Module
2661573010	Sitagliptin phosphate (substance)	en	Fully specified name	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
2675154010	Sitagliptin phosphate	en	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	SNOMED CT core
3234201000005117	sitagliptinphosphat	da	Synonym (core metadata concept)	Active	Entire term case insensitive (core metadata concept)	Danish module (core metadata concept)